The emergence of infective coronavirus (SARS-CoV-2) has generated significant global concern, especially with the disease (“COVID-19”) achieving pandemic status. While laboratory testing of nasopharyngeal swabs for active virus load represents the gold standard of infection testing and tracing, implementing on-site rapid testing for COVID-19 allows the potential for businesses to significantly reduce the waiting times associated with COVID-19 testing while also help maintain a COVID-safe workplace. In this light, AusHealth has partnered with Innovation Scientific and is now offering InnoScreen COVID-19 Antigen Rapid Test kits for sale to business clients.
On-site screening may provide an immediate indication as to the possible infectivity of any individual on a given worksite, which will allow management to take swift and appropriate actions to maintain workplace safety. However, on-site rapid testing is not a substitute for maintaining good practice when it comes to infection control, COVID-safe plans and hygiene procedures should also be implemented.
Yes, it is. Find the InnoScreen COVID-19 Antigen Rapid Test Device listed on the TGA site here.
Each kit contains all the equipment required to perform 20 individual tests.
Tests must be conducted or supervised by a health practitioner as defined in Section 3 of the Therapeutic Goods Act 1989. Additionally, they must undergo training provided by AusHealth on correct use of the device and interpretation of the test result.
Yes, training can be found on this page. Video, phone and conferencing support is also available.
All results obtained from the InnoScreen COVID-19 Antigen Rapid Test kits should be considered indicative only and should not be relied upon for diagnostic purposes. The manufacturer has stated a test specificity of 99.25% and an overall sensitivity rate of 83.33%. This means that there may be cases where a COVID-19-positive donor returns a negative test, particularly in the very early and late stages of infection due to the reduced viral load at these time points. For this reason, any symptomatic donors that return a negative test should be sent for immediate confirmation testing at a COVID-19 testing clinic and should not return to the workplace until a negative test result is obtained.
AusHealth is able to sell to government, health practitioners and companies who employs or engages a health practitioner as defined in Section 3 of the Therapeutic Goods Act 1989 who is responsible for performing or supervising the performance of the test and undertakes suitable training on the testing device (training pack supplied by AusHealth).
Further clarification of these rules can be found on the TGA website here.
If you purchase the InnoScreen COVID-19 Antigen Rapid test kit you need to meet the criteria set out by the TGA, namely "Conditions specific to COVID-19 rapid antigen point-of-care tests". This criteria is:
As an ongoing effort to streamline the use of the rapid tests and to ensure the kits are performed in accordance with the guidelines set by TGA, we need to ensure that the you understand how to perform the tests proficiently and are trained sufficiently.
We therefore have a link to our tutorial and the brochures provided by Innovation Scientific. Please watch the tutorial and familiarise yourself with the product before using the test kits.
Please call Siobhan from AusHealth on 0407 720 368 for further training or any questions you may have. Our technical team is there if you need advice or further training or support. On completing the training, please fill out the online form below and submit it for our records.